Recurrent cancer-associated R1523H/C mutations in the AWS domain of human SETD2 destabilize the catalytic core and impair H3K36me3 deposition: molecular and cellular insights

SET domain–containing protein 2 (SETD2) is the primary histone methyltransferase responsible for trimethylation of histone H3 lysine 36 (H3K36me3) in higher eukaryotes, a key epigenetic mark associated with actively transcribed chromatin and essential processes such as transcription, DNA repair, RNA splicing, and DNA methylation. Recurrent SETD2 alterations are frequently observed in cancers and are linked to defective H3K36me3 deposition and tumor progression. While mutations in the catalytic SET domain have been partially documented, the functional and structural consequences of recurrent mutations in other regions of the catalytic core, particularly within the domain associated with SET (AWS), remain poorly understood. We combined biochemical assays, cellular studies in SETD2-knockout (KO) HEK293T cells, X-ray crystallography, and molecular dynamics (MD) simulations to investigate the impact of the R1523C and R1523H mutations on SETD2 activity, stability, and structure. Biochemical analyses showed that the R1523C and R1523H mutations markedly reduced H3K36 methyltransferase activity across all methylation states. These variants also exhibited decreased intrinsic protein thermal stability and an increased propensity to aggregate in vitro. In cellular models, both mutants displayed decreased H3K36me3 deposition and enhanced aggregation and ubiquitination, consistent with a loss-of-function phenotype. Structural analysis revealed that the R1523H mutation disrupted local interactions within the AWS domain, particularly in the zinc-binding region. MD simulations further demonstrated increased local flexibility and destabilization of the AWS domain. Our findings support the idea that the recurrent cancer-associated mutations affecting residue R1523 (notably R1523H) within the SETD2 AWS domain impair enzymatic activity by destabilizing protein structure and promoting aggregation. Although the AWS domain is not directly catalytic, our results underline its critical role in maintaining the structural integrity and dynamic organization of the catalytic core of the enzyme. These results highlight a mechanism by which mutations outside the catalytic SET domain compromise SETD2 function and contribute to defective H3K36me3 deposition in cancer. More broadly, this study provides mechanistic insights into how cancer-associated mutations disrupt the stability and activity of this essential epigenetic regulator.

Authors

Institutions

Publication Details

Journal
Cellular & Molecular Biology Letters
Published
2026-11-15
DOI
https://doi.org/10.1186/s11658-026-01047-y
Primary Topic
Cancer-related gene regulation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Recurrent cancer-associated R1523H/C mutations in the AWS domain of human SETD2 destabilize the catalytic core and impair H3K36me3 deposition: molecular and cellular insights

Amira Al Mahi, Ariel Méchaly, Christina Michail, Xionghao Li et al.
Cellular & Molecular Biology Letters
Cancer-related gene regulation
article

Recurrent cancer-associated R1523H/C mutations in the AWS domain of human SETD2 destabilize the catalytic core and impair H3K36me3 deposition: molecular and cellular insights

Amira Al Mahi, Ariel Méchaly, Christina Michail, Xionghao Li, Benoı̂t Gigant, Miryana Hémadi, Frédérique Deshayes, Ahmed Haouz, 徐希明, Fernando Rodrigues‐Lima, Li Wang, Duo Cai, Clémence Paumier, Linh-Chi Bui, Rebecca Scheidecker
article en

Abstract

SET domain–containing protein 2 (SETD2) is the primary histone methyltransferase responsible for trimethylation of histone H3 lysine 36 (H3K36me3) in higher eukaryotes, a key epigenetic mark associated with actively transcribed chromatin and essential processes such as transcription, DNA repair, RNA splicing, and DNA methylation. Recurrent SETD2 alterations are frequently observed in cancers and are linked to defective H3K36me3 deposition and tumor progression. While mutations in the catalytic SET domain have been partially documented, the functional and structural consequences of recurrent mutations in other regions of the catalytic core, particularly within the domain associated with SET (AWS), remain poorly understood. We combined biochemical assays, cellular studies in SETD2-knockout (KO) HEK293T cells, X-ray crystallography, and molecular dynamics (MD) simulations to investigate the impact of the R1523C and R1523H mutations on SETD2 activity, stability, and structure. Biochemical analyses showed that the R1523C and R1523H mutations markedly reduced H3K36 methyltransferase activity across all methylation states. These variants also exhibited decreased intrinsic protein thermal stability and an increased propensity to aggregate in vitro. In cellular models, both mutants displayed decreased H3K36me3 deposition and enhanced aggregation and ubiquitination, consistent with a loss-of-function phenotype. Structural analysis revealed that the R1523H mutation disrupted local interactions within the AWS domain, particularly in the zinc-binding region. MD simulations further demonstrated increased local flexibility and destabilization of the AWS domain. Our findings support the idea that the recurrent cancer-associated mutations affecting residue R1523 (notably R1523H) within the SETD2 AWS domain impair enzymatic activity by destabilizing protein structure and promoting aggregation. Although the AWS domain is not directly catalytic, our results underline its critical role in maintaining the structural integrity and dynamic organization of the catalytic core of the enzyme. These results highlight a mechanism by which mutations outside the catalytic SET domain compromise SETD2 function and contribute to defective H3K36me3 deposition in cancer. More broadly, this study provides mechanistic insights into how cancer-associated mutations disrupt the stability and activity of this essential epigenetic regulator.

Cellular & Molecular Biology Letters
Centre National de la Recherche Scientifique (FR), Inserm (FR), Institut Pasteur (FR), Université Paris Cité (FR), Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR), Université Paris Sciences et Lettres (FR), Université Paris-Saclay (FR), Institut de Biologie Intégrative de la Cellule (FR), Interfaces Traitements Organisation et Dynamique des Systèmes (FR), The Affiliated Yongchuan Hospital of Chongqing Medical University (CN), Unit of Functional and Adaptive Biology (FR), Biologie Moléculaire Structurale et Processus Infectieux (FR), Ocean University of China (CN), Institut Curie (FR)
Cancer-related gene regulation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon